NR2A

By Targets:	Adrenergic Receptor (2) Calcium Channel (2) iGluR (14) Influenza Virus (2) NO Synthase (4) Potassium Channel (3) Reference Standards (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Infection (2) Neurological Disease (14)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Targets Recommended: Progesterone Receptor FXR Constitutive Androstane Receptor Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12882A

Ifenprodil tartrate 5+ Cited Publications NP-120 tartrate; RC-61-91 tartrate	iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus	Infection Neurological Disease
Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC₅₀ of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease ^[2] .

HY-P0117

Tat-NR2B9c 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy ^[2] .

HY-12882

Ifenprodil Maximum Cited Publications 10 Publications Verification NP-120; RC-61-91	iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus	Infection Neurological Disease
Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC₅₀ of 6.6 µM). Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease ^[2] .

HY-12881

Eliprodil SL-820715	iGluR	Neurological Disease
Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM).

HY-P0117A

Tat-NR2B9c TFA 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-12962

NMDA-IN-1	iGluR	Neurological Disease
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.

HY-107698

PMPA (NMDA antagonist)	iGluR	Neurological Disease
PMPA (NMDA antagonist) is an NMDA receptor antagonist with K_i values of 0.84, 2.74, 3.53 and 4.16 μM for *NR2A, NR2B, NR2C* and *NR2D*, respectively .

HY-107699

PPPA	iGluR	Neurological Disease
PPPA is a competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors ^[2].

HY-116142

CP-283097	iGluR	Neurological Disease
CP-283097 is an orally active and conformationally restricted and *NR2B* subtype-selective NMDA antagonist. CP-283097 efficiently competitively inhibits the binding of [³H]CP-101,606 to the rat meninges, with an IC₅₀ value of 18 nM. CP-283097 exhibits nearly complete inhibition of the current mediated by the NR2B receptor (IC₅₀ = 206 nM), while the inhibitory effect on the NR2A or NR2C receptors is very weak. CP-283097 demonstrates excellent central nervous system permeability and in vivo efficacy in animal models. CP-283097 can be used for neurological diseases related to excessive activation of NMDA receptors .

HY-12882AR

Ifenprodil tartrate (Standard) NP-120 tartrate (Standard); RC-61-91 tartrate (Standard)	iGluR Potassium Channel Reference Standards	Neurological Disease
Ifenprodil (tartrate) (Standard) is the analytical standard of Ifenprodil (tartrate). This product is intended for research and analytical applications. Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator ^[2].

HY-105353

CEB-1604	iGluR	Neurological Disease
CEB-1604 is an NMDA receptor antagonist. CEB-1604 inhibits NMDA-induced currents in oocytes transfected with NMDA receptor isoforms (NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D) with IC₅₀ values ranging from 5 to 12 μM. CEB-1604 abolishes NMDA-dependent epileptiform discharges in rat cortical wedge preparations and reduces the depolarizing effects of NMDA. CEB-1604 can be used in the research field of neurological damage diseases .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 ^[2].

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-RS27654

Grin2a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Grin2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Grin2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Grin2a Rat Pre-designed siRNA Set A Grin2a Rat Pre-designed siRNA Set A

HY-RS05804

GRIN2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GRIN2A Human Pre-designed siRNA Set A contains three designed siRNAs for GRIN2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GRIN2A Human Pre-designed siRNA Set A GRIN2A Human Pre-designed siRNA Set A

HY-12962A

NMDA-IN-1 dihydrochloride	iGluR	Neurological Disease
NMDA-IN-1 dihydrochloride is a selective NMDA NR2B antagonist with a Ki of 0.85 nM; NR2B Ca₂₊ influx IC₅₀ is 9.7 nM. NMDA-IN-1 dihydrochloride inhibits Glu/Gly stimulated Ca₂₊ flux in Ltk- cells expressing the hNR1a/NR2B with a IC₅₀ of 9.7 nM. NMDA-IN-1 dihydrochloride has no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor. NMDA-IN-1 dihydrochloride shows excellent activity in the mechanical hyperalgesia assay in rats. NMDA-IN-1 dihydrochloride can be used for the studies of stroke, parkinson, and neuropathic pain .

HY-RS21136

Grin2a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Grin2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Grin2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Grin2a Mouse Pre-designed siRNA Set A Grin2a Mouse Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area

HY-P0117

Tat-NR2B9c 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy ^[2] .

HY-P0117A

Tat-NR2B9c TFA 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 ^[2].

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12882A

Ifenprodil tartrate 5+ Cited Publications NP-120 tartrate; RC-61-91 tartrate	Alkaloids Piperidine Alkaloids Neurological Disease Classification of Application Fields Crassulaceae Sedum sarmentosum Bunge Plants Disease Research Fields Source Classification	iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus
Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC₅₀ of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease ^[2] .

HY-12882AR

Ifenprodil tartrate (Standard) NP-120 tartrate (Standard); RC-61-91 tartrate (Standard)	Alkaloids Piperidine Alkaloids Crassulaceae Sedum sarmentosum Bunge Plants Source Classification	iGluR Potassium Channel Reference Standards
Ifenprodil (tartrate) (Standard) is the analytical standard of Ifenprodil (tartrate). This product is intended for research and analytical applications. Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator ^[2].

Species:	Human (2)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701139A

	HNF4A Protein, Human (HEK293, His) 1 Publications Verification FRTS4; HNF4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; MODY; MODY1; NR2A1; NR2A21; TCF; TCF-14; TCF14	Human	HEK293
	HNF 4 alpha, a nuclear transcription factor, forms homodimers to bind DNA. It regulates gene expression, including hepatocyte nuclear factor 1 alpha, impacting hepatic genes. Its involvement extends to liver, kidney, and intestinal development. Mutations associate with autosomal dominant non-insulin-dependent diabetes mellitus type I. The gene exhibits biased expression in the duodenum (RPKM 37.7) and colon (RPKM 32.8), among other tissues. HNF4A Protein, Human (HEK293, His) is the recombinant human-derived HNF 4 alpha, expressed by HEK293 , with C-10*His labeled tag.

HY-P701139

	HNF4A Protein, Human (HEK293, His, solution) FRTS4; HNF4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; MODY; MODY1; NR2A1; NR2A21; TCF; TCF-14; TCF14	Human	HEK293
	HNF 4 alpha, a nuclear transcription factor, forms homodimers to bind DNA. It regulates gene expression, including hepatocyte nuclear factor 1 alpha, impacting hepatic genes. Its involvement extends to liver, kidney, and intestinal development. Mutations associate with autosomal dominant non-insulin-dependent diabetes mellitus type I. The gene exhibits biased expression in the duodenum (RPKM 37.7) and colon (RPKM 32.8), among other tissues. HNF4A Protein, Human (HEK293, His, solution) is the recombinant human-derived HNF 4 alpha, expressed by HEK293 , with C-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (4) Rabbit (4)
Reactivity:	Human (8) Rat (4) Mouse (4)
Application:	IHC-P (4) ICC/IF (2) IP (3) WB (4) ChIP (2) FC (5) ELISA (5)
Isotype:	IgG (4) IgG1 (2) IgG2b (2)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (5) Recombinant (2)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84519

	GRIN2A Antibody (YA4216) LKS; EPND; FESD; NR2A; GluN2A; NMDAR2A	FC, ELISA	Human
	GRIN2A Antibody (YA4216) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRIN2A.

HY-P84519A

	GRIN2A Antibody (YA4216)(PBS only) LKS; EPND; FESD; NR2A; GluN2A; NMDAR2A	FC, ELISA	Human
	GRIN2A Antibody (YA4216) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRIN2A.

HY-P83775

	HNF 4 alpha Antibody (YA3571) TCF; HNF4; MODY; FRTS4; MODY1; NR2A1; TCF14; HNF4a7; HNF4a8; HNF4a9; NR2A21; TCF-14; HNF4alpha	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	HNF 4 alpha Antibody (YA3571) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HNF 4 alpha.

HY-P84307

	HNF 4 alpha Antibody (YA4004) TCF; HNF4; MODY; FRTS4; MODY1; NR2A1; TCF14; HNF4a7; HNF4a8; HNF4a9; NR2A21; TCF-14; HNF4alpha	IHC-P, FC, ELISA	Human
	HNF 4 alpha Antibody (YA4004) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HNF 4 alpha.

HY-P81445

	HNF 4 alpha Antibody (YA1190) TCF; HNF4; MODY; FRTS4; MODY1; NR2A1; TCF14; HNF4a7; HNF4a8; HNF4a9; NR2A21; TCF-14; HNF4alpha	WB, IP, ChIP	Human, Mouse, Rat
	HNF 4 alpha Antibody (YA1190) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HNF 4 alpha.

HY-P81445A

	HNF 4 alpha Antibody (YA1190)(PBS only) TCF; HNF4; MODY; FRTS4; MODY1; NR2A1; TCF14; HNF4a7; HNF4a8; HNF4a9; NR2A21; TCF-14; HNF4alpha	WB, IP, ChIP	Human, Mouse, Rat
	HNF 4 alpha Antibody (YA1190) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HNF 4 alpha.

HY-P84307A

	HNF 4 alpha Antibody (YA4004)(PBS only) TCF; HNF4; MODY; FRTS4; MODY1; NR2A1; TCF14; HNF4a7; HNF4a8; HNF4a9; NR2A21; TCF-14; HNF4alpha	IHC-P, FC, ELISA	Human
	HNF 4 alpha Antibody (YA4004) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HNF 4 alpha.

HY-P86160

	HNF 4 alpha Antibody (YA5852) HNF4A; HNF4; NR2A1; TCF14; Hepatocyte nuclear factor 4-alpha; HNF-4-alpha; Nuclear receptor subfamily 2 group A member 1; Transcription factor 14; TCF-14; Transcription factor HNF-4	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	HNF 4 alpha Antibody (YA5852) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HNF 4 alpha.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS27654

Grin2a Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Grin2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Grin2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS05804

GRIN2A Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
GRIN2A Human Pre-designed siRNA Set A contains three designed siRNAs for GRIN2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS21136

Grin2a Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Grin2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Grin2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides